Stephan Willems - LAA occlusion should be for (N)OAC in-tolerant patients. Not everyone!More info
Debate: Is LAA occlusion an alternative to oral anticoagulation in low bleeding risk patients?
LAA occlusion should be considered for (N)OAC in-tolerant patients primarily. NOT for everyone!
David Hildick Smith - What’s new: clinical data published and presented since last year
New clinical data for left atrial appendage occlusion therapy, presented & published in 2016. Includes a critical review of the Stroke Prevention section in the 2016 ESC Atrial Fibrillation guidelines.
Matthew Price - What’s new: cost effectiveness and health economics
Why might LAA occlusion therapy be cost effective, despite a high procedural cost? This presentation is an overview of the health economics data available for left atrial appendage closure therapy.
Here you will find the a selected series of talks and performances focused on left atrial appendage occlusion. They are seleced from conferences, events -- and the best of the web. More than 20 talks are now avialable.
Links & Resources
Find a comprehensive overview of relevant information about left atrial appendage occlusion and stroke prevention and related societies and industry.
The Atrial Fibrillation Association (AFA) is a UK registered charity which focuses on raising awareness of Atrial Fibrillation (AF) by providing information and support materials for patients and medical professionals involved in detecting, diagnosing and managing Atrial Fibrillation.